Related Experiment Videos
[Features of oral cavity microflora in congenital cleft lip and palate]
Insights
Congenital defects like cleft lip and palate increase infection risk from bacteria such as Staphylococcus and E. coli. A pyophage product showed significant sensitivity against these drug-resistant bacterial strains.
Area of Science:
- Medical Microbiology
- Pediatric Pathology
- Genetics
Context:
- Cheiloschisis and uranoschisis (cleft lip and palate) are significant congenital defects.
- These conditions predispose children to severe purulent inflammatory infections.
- Common pathogens include Staphylococcus spp., Streptococcus spp., Pseudomonas aeruginosa, and Escherichia coli.
Purpose:
- To investigate the drug resistance patterns of bacterial pathogens associated with cleft lip and palate.
- To evaluate the efficacy of a commercial pyophage product against these multi-drug resistant bacteria.
Summary:
- Bacterial isolates from children with cleft lip and palate exhibited multi-drug resistance.
- Resistance was linked to R plasmids with varying molecular weights (3.0-110.0 MD).
- A commercial pyophage product demonstrated notable sensitivity against Staphylococcus, Streptococcus, E. coli, P. aeruginosa, and Acinetobacter strains.
Impact:
- Highlights the challenge of antibiotic resistance in vulnerable pediatric populations.
- Suggests pyophage therapy as a potential alternative or adjunct treatment for infections in these patients.
- Provides data on plasmid-mediated drug resistance in clinically relevant bacteria.
Abstract:
Cheilloschisis and uranoschisis are the most important congenital defects in children. This pathology increases the incidence of purulent inflammatory affections due to Staphylococcus spp., Streptococcus spp., Pseudomonas aeruginosa and Escherichia coli. The isolates were found to have multiple drug resistance determined by R plasmids of different incompatibility groups. The molecular weights of the plasmids were: 3.0, 8.0 and 9.0 MD in Staphylococcus spp., 90.0 and 110.0 MD in P. aeruginosa and P. putida, 33.0, 38.0, 49.0 and 53.0 MD in E. coli. 87.0 per cent of the Staphylococcus strains, 78.9 per cent of the Streptococcus strains, 83.3 per cent of the E. coli strains, 74.0 per cent of the P. aeruginosa strains and 66.6 per cent of the Acinetobacter stains were shown to be sensitive to the commercial pyophage product used in the study.